Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stentys SAS

This article was originally published in Start Up

Executive Summary

The design of currently marketed stents is not optimal in treating stenosis in or next to coronary bifurcations. Stentys, founded by noted cardiologist and entrepreneur Jacques Séguin, MD, PhD, aims to improve on outcomes while keeping things simple. It believes its bifurcation stent will be as easy for cardiologists to use as conventional stents, but that its novel design will provide superior clinical results by enabling full opening and scaffolding of the side branch.

Related Content

Stentys' IPO: European Public Markets Opening For Device Companies?
Cappella: Can a New Twist On An Old Idea Solve the Bifurcation Challenge?
Tryton Medical: Going Against the Flow in Bifurcated Stents
Start-Up Quarterly Statistics, Q1 2008
Minvasys: Tailoring the Stent to Fit the Lesion in Bifurcations
Start-Up Previews
CoreValve: A Surgeon Moves Heart Valves to the Cath Lab
Bifurcation Stenting: The Next Generation
Bifurcation Stenting: The Next Generation
Cappella Inc.


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts